文献速递牙体牙髓病

硅酸钙基根管内封药:临床与实验室证据的范围综述

Current perspectives on calcium silicate-based intracanal medicaments: A scoping review of clinical and laboratory evidence.
PubMed 文献 · J Dent · 2024-08-17

该范围综述系统检索了硅酸钙基根管内封药的临床与实验室证据,纳入15项研究。结果显示其具有可接受的生物相容性、碱性pH和高钙离子释放,但抗菌活性低于传统氢氧化钙,且存在牙齿变色问题。现有证据有限,尚不足以推荐常规临床应用。

要点

  • 硅酸钙基根管内封药生物相容性可接受,pH呈碱性且钙离子释放高。
  • 其抗菌活性低于传统氢氧化钙制剂,且牙齿变色超出临床可接受阈值。
  • 证据尚不充分,不能推荐用于常规临床实践。

核心结论

  • 硅酸钙基根管内封药具有可接受的生物相容性、碱性pH和高钙离子释放,但抗菌活性低于传统氢氧化钙且牙齿变色问题显著,现有证据尚不足以推荐常规临床应用。

研究设计与样本

  • 范围综述,方案预先注册(https://osf.io/rnyuv/),在Cochrane Library、EMBASE、PubMed/MEDLINE、SciVerse Scopus和Web of Science进行系统检索,最终纳入15项研究。

主要发现

  • 纳入研究多来自巴西,主要关注Bio-C Temp(Angelus)。
  • 研究显示可接受的生物相容性、碱性pH和高钙离子释放。
  • 抗菌活性低于传统氢氧化钙制剂。
  • 牙齿变色超出临床可接受阈值是显著问题。
  • 单例临床病例报告显示根尖周愈合和牙根发育的潜力,但证据非常有限。

临床怎么用

  • 鉴于抗菌活性较低和牙齿变色风险,硅酸钙基根管内封药不能推荐用于常规临床实践。

局限性

  • 现有证据为初步性,需要高质量临床试验确定其临床疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Intracanal medicaments, primarily calcium hydroxide, play a significant role in optimizing root canal disinfection. Recently, calcium silicate-based intracanal medicaments have emerged as potential alternatives. This scoping review sought to map the available evidence concerning the clinical and laboratory properties of these bioceramic medicaments. DATA: The study protocol was registered a priori (https://osf.io/rnyuv/) and a systematic search strategy using relevant MeSH terms was employed. SOURCES: The search was conducted across databases including the Cochrane Library, EMBASE, PubMed/MEDLINE, SciVerse Scopus, and Web of Science. STUDY SELECTION: Studies that investigated the clinical and laboratory properties of calcium silicate-based intracanal medicaments were included. CONCLUSIONS: Out of 1008 potentially relevant articles, 15 met the inclusion criteria. The majority of the studies came from Brazil, primarily focusing on Bio-C Temp (Angelus). The studies revealed acceptable biocompatibility, alkaline pH, and high calcium ion release. However, they showed reduced antibacterial activity compared to conventional calcium hydroxide formulations. Tooth discoloration beyond clinically acceptable thresholds was also a significant concern. A single clinical case report exhibited potential for periapical healing and root development, though this evidence is very limited. While current evidence is preliminary, high-quality clinical trials are essential to determine their clinical efficacy and safety in endodontic treatments. CLINICAL RELEVANCE: Calcium silicate-based intracanal medicaments have lower antibacterial activity and potential for tooth discoloration compared to conventional calcium hydroxide-based medicaments. Given the available evidence, they cannot be recommended for routine clinical practice.

来源:J Dent,查看原文。版权归原作者所有。

引用

  1. de Araújo LP, Immich F, da Rosa WLO, et al. Current perspectives on calcium silicate-based intracanal medicaments: A scoping review of clinical and laboratory evidence. J Dent. 2024. PMID: 39159742. doi:10.1016/j.jdent.2024.105311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。